Summary:
- The FDA has approved Leqembi (lecanemab-irmb) for subcutaneous injection, which is a new maintenance dosing option for the treatment of early Alzheimer's disease.
- Leqembi is an antibody that targets and removes amyloid-beta, a protein that builds up in the brains of people with Alzheimer's disease, potentially slowing the progression of the disease.
- This new subcutaneous injection form of Leqembi provides a more convenient dosing option for patients, as it can be administered at home by a healthcare provider or the patient themselves, rather than requiring an intravenous infusion.